# MiniMed Group Inc. (MMED) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Technology. Price $23.29, market value $6.6 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). MiniMed Group Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 2.1×**. Each dollar of revenue is priced at 2.1×.
- **Price / book: 1.8×**. The shares trade at 1.8× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -6.4%** (5-yr avg -12.4%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 54.2%**. MiniMed Group Inc. keeps 54.2% of revenue after the direct cost of what it sells.
- **Operating margin: -6.1%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -10.7%**. The company reported a net loss over the last twelve months.
- **Return on equity: -9.2%**. Return on equity is negative because earnings are negative.
- **Return on assets: -7.2%**. Each dollar of assets produces -7.2% of profit.

## Growth
- **Revenue growth (1 yr): 14.3%**. Revenue grew 14.3% over the last year.
- **EPS growth (1 yr): -54.8%**. Earnings per share fell 54.8%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 1.92** (quick 1.92). Current assets cover the next year's liabilities 1.92 times.
- **Altman Z-score: 5.65**. A Z-score of 5.65 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. MiniMed Group Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (12 analysts). 12 analysts cover MiniMed Group Inc.; the consensus is buy, with an average price target of $24.83 (+7% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -4.7%** (118.6% above the low). Trading within 5% of its 52-week high.
- **RSI (14-day): 71**. An RSI of 71 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 0.80** (volatility 60%). Beta of 0.80 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=MMED · Page: https://foliofundamentals.com/stocks/mmed

Not investment advice.